Merus N.V. (MRUS) Reports Q2 Loss of EUR0.40/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. VRNS
2. CRWV
3. TSLA
4. JBHT
5. GPRK
6. SCHW
7. TRV
8. TFC
9. SPY
10. AA

Go back to Merus N.V. (MRUS) Reports Q2 Loss of EUR0.40/Share

Merus Announces Second Quarter 2016 Financial Results and Reviews Recent Clinical Progress and Corporate Developments

August 8, 2016 7:00 AM EDT

UTRECHT, The Netherlands, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the second quarter ended June 30, 2016 and provided a review of recent accomplishments and clinical development plans.

We ended the second quarter with 71.1 million of cash and cash equivalents, which provides us with the funding to achieve several development milestones, said Ton Logtenberg, PhD, Chief Executive Officer of Merus. We look forward to reporting on the progress of our lead HER2 x HER3 bispecific candidate, MCLA-128, our... More